SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

Inovio Q3'26 Earnings Preview: EPS Estimate at (0.20) USD

Inovio is set to report Q3'26 results November 10 after the market closes. Revenue is estimated at USD 0, with EPS expected at (0.20) USD.

INO
SquawkNews Desk

INO (Inovio Pharmaceuticals, Inc.) is set to announce its Q3'26 results on November 10, after the market closes. The earnings are expected to be disclosed at 4:05 PM ET (9:05 PM UTC).For Q3'26, revenue estimate is 0 USD with EPS (earnings per share) anticipated at (0.20) USD. Learn more details at…

Related stories

CorMedix to Acquire Heron Therapeutics Assets for $145 Million and 14.6 Million Shares CorMedix agreed to acquire substantially all of Heron Therapeutics’ assets for $145 million in cash, subject to adjustments, and 14,583,333 CorMedix shares. The deal also includes M impact | EQUITY | Nov 09, 2026, 01:04 PM UTC Superior Group of Companies Q3 2026 Earnings Call Begins The company's quarterly earnings call has begun. M impact | EQUITY | Nov 09, 2026, 12:57 PM UTC Roivant Sciences Q2 2027 Earnings Call Begins Roivant Sciences' quarterly earnings call has begun. M impact | EQUITY | Nov 09, 2026, 12:57 PM UTC Al Manar Financing and Leasing Q3 Profit 975,834 Dinars M impact | EQUITY | Nov 09, 2026, 12:56 PM UTC RadNet Reports Q3 Revenue of $638.3 Million, Raises 2026 Guidance Third-quarter 2026 revenue rose 22.1% year over year to $638.3 million, and Adjusted EBITDA increased 23.8% to $105.0 million. Net income attributable to common stockholders was $4 M impact | EQUITY | Nov 09, 2026, 12:53 PM UTC Bicara Reports Q3 2026 Net Loss of $71.2 Million Bicara reported a net loss of $71.2 million for the third quarter of 2026, versus $36.3 million a year earlier. It had $442.3 million in cash, cash equivalents and marketable secur M impact | EQUITY | Nov 09, 2026, 12:53 PM UTC